^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | FT596 (CD19 inhibitor, IL-15R stimulant, CD16A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2216: Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response
Published date:
06/23/2020
Excerpt:
In vivo, both FT596 and FT819 showed stable levels of tumor cell clearance against the CD19+ acute lymphoblastic leukemia cell line NALM6, comparable to that of primary CAR19 T cells (p*<0.0001 for FT596, FT819 or Primary CART vs NALM6 alone)
DOI:
10.1158/1538-7445.AM2020-2216
